Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Brain Commun
2020 Jan 01;22:fcaa162. doi: 10.1093/braincomms/fcaa162.
Show Gene links
Show Anatomy links
Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies.
Absalom NL
,
Liao VWY
,
Kothur K
,
Indurthi DC
,
Bennetts B
,
Troedson C
,
Mohammad SS
,
Gupta S
,
McGregor IS
,
Bowen MT
,
Lederer D
,
Mary S
,
De Waele L
,
Jansen K
,
Gill D
,
Kurian MA
,
McTague A
,
Møller RS
,
Ahring PK
,
Dale RC
,
Chebib M
.
???displayArticle.abstract???
Variants in the GABRB3 gene encoding the β3-subunit of the γ-aminobutyric acid type A ( receptor are associated with various developmental and epileptic encephalopathies. Typically, these variants cause a loss-of-function molecular phenotype whereby γ-aminobutyric acid has reduced inhibitory effectiveness leading to seizures. Drugs that potentiate inhibitory GABAergic activity, such as nitrazepam, phenobarbital or vigabatrin, are expected to compensate for this and thereby reduce seizure frequency. However, vigabatrin, a drug that inhibits γ-aminobutyric acid transaminase to increase tonic γ-aminobutyric acid currents, has mixed success in treating seizures in patients with GABRB3 variants: some patients experience seizure cessation, but there is hypersensitivity in some patients associated with hypotonia, sedation and respiratory suppression. A GABRB3 variant that responds well to vigabatrin involves a truncation variant (p.Arg194*) resulting in a clear loss-of-function. We hypothesized that patients with a hypersensitive response to vigabatrin may exhibit a different γ-aminobutyric acid A receptor phenotype. To test this hypothesis, we evaluated the phenotype of de novo variants in GABRB3 (p.Glu77Lys and p.Thr287Ile) associated with patients who are clinically hypersensitive to vigabatrin. We introduced the GABRB3 p.Glu77Lys and p.Thr287Ile variants into a concatenated synaptic and extrasynaptic γ-aminobutyric acid A receptor construct, to resemble the γ-aminobutyric acid A receptor expression by a patient heterozygous for the GABRB3 variant. The mRNA of these constructs was injected into Xenopus oocytes and activation properties of each receptor measured by two-electrode voltage clamp electrophysiology. Results showed an atypical gain-of-function molecular phenotype in the GABRB3 p.Glu77Lys and p.Thr287Ile variants characterized by increased potency of γ-aminobutyric acid A without change to the estimated maximum open channel probability, deactivation kinetics or absolute currents. Modelling of the activation properties of the receptors indicated that either variant caused increased chloride flux in response to low concentrations of γ-aminobutyric acid that mediate tonic currents. We therefore propose that the hypersensitivity reaction to vigabatrin is a result of GABRB3 variants that exacerbate GABAergic tonic currents and caution is required when prescribing vigabatrin. In contrast, drug strategies increasing tonic currents in loss-of-function variants are likely to be a safe and effective therapy. This study demonstrates that functional genomics can explain beneficial and adverse anti-epileptic drug effects, and propose that vigabatrin should be considered in patients with clear loss-of-function GABRB3 variants.
Absalom,
Functional genomics of epilepsy-associated mutations in the GABAA receptor subunits reveal that one mutation impairs function and two are catastrophic.
2019, Pubmed,
Xenbase
Absalom,
Functional genomics of epilepsy-associated mutations in the GABAA receptor subunits reveal that one mutation impairs function and two are catastrophic.
2019,
Pubmed
,
Xenbase
Anstee,
Mutations in the Gabrb1 gene promote alcohol consumption through increased tonic inhibition.
2013,
Pubmed
Butler,
De novo variants in GABRA2 and GABRA5 alter receptor function and contribute to early-onset epilepsy.
2018,
Pubmed
Chiron,
The pharmacologic treatment of Dravet syndrome.
2011,
Pubmed
Delahanty,
Maternal transmission of a rare GABRB3 signal peptide variant is associated with autism.
2011,
Pubmed
French,
Refractory epilepsy: one size does not fit all.
2006,
Pubmed
Fritschy,
Five subtypes of type A gamma-aminobutyric acid receptors identified in neurons by double and triple immunofluorescence staining with subunit-specific antibodies.
1992,
Pubmed
Gataullina,
Gene mutations in paediatric epilepsies cause NMDA-pathy, and phasic and tonic GABA-pathy.
2019,
Pubmed
Gielen,
Benzodiazepines modulate GABAA receptors by regulating the preactivation step after GABA binding.
2012,
Pubmed
,
Xenbase
Hernandez,
A structural look at GABAA receptor mutations linked to epilepsy syndromes.
2019,
Pubmed
Hernandez,
Altered inhibitory synapses in de novo GABRA5 and GABRA1 mutations associated with early onset epileptic encephalopathies.
2019,
Pubmed
Hernandez,
GABA A Receptor Coupling Junction and Pore GABRB3 Mutations are Linked to Early-Onset Epileptic Encephalopathy.
2017,
Pubmed
Hernández Vega,
Reversible vigabatrin-induced life-threatening encephalopathy.
2014,
Pubmed
Janve,
Epileptic encephalopathy de novo GABRB mutations impair γ-aminobutyric acid type A receptor function.
2016,
Pubmed
Johannesen,
Phenotypic spectrum of GABRA1: From generalized epilepsies to severe epileptic encephalopathies.
2016,
Pubmed
,
Xenbase
Kash,
Charged residues in the beta2 subunit involved in GABAA receptor activation.
2004,
Pubmed
Kothur,
Diagnostic yield of targeted massively parallel sequencing in children with epileptic encephalopathy.
2018,
Pubmed
Kuenzle,
Adverse effects of vigabatrin in Angelman syndrome.
1998,
Pubmed
Laverty,
Cryo-EM structure of the human α1β3γ2 GABAA receptor in a lipid bilayer.
2019,
Pubmed
Liao,
Concatenated γ-aminobutyric acid type A receptors revisited: Finding order in chaos.
2019,
Pubmed
Lien,
A second patient with a De Novo GABRB1 mutation and epileptic encephalopathy.
2016,
Pubmed
Lux,
The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.
2005,
Pubmed
Maljevic,
Spectrum of GABAA receptor variants in epilepsy.
2019,
Pubmed
Masiulis,
GABAA receptor signalling mechanisms revealed by structural pharmacology.
2019,
Pubmed
Mattison,
SLC6A1 variants identified in epilepsy patients reduce γ-aminobutyric acid transport.
2018,
Pubmed
Mortensen,
GABA Potency at GABA(A) Receptors Found in Synaptic and Extrasynaptic Zones.
2011,
Pubmed
Møller,
Mutations in GABRB3: From febrile seizures to epileptic encephalopathies.
2017,
Pubmed
,
Xenbase
Møller,
Gene Panel Testing in Epileptic Encephalopathies and Familial Epilepsies.
2016,
Pubmed
Nasrallah,
Activity-dependent γ-aminobutyric acid release controls brain cortical tissue slice metabolism.
2011,
Pubmed
Niturad,
Rare GABRA3 variants are associated with epileptic seizures, encephalopathy and dysmorphic features.
2017,
Pubmed
,
Xenbase
Noebels,
GABRB3, Epilepsy, and Neurodevelopment
2012,
Pubmed
Nusser,
Differences in synaptic GABA(A) receptor number underlie variation in GABA mini amplitude.
1997,
Pubmed
Ortinski,
Deletion of the GABA(A) receptor alpha1 subunit increases tonic GABA(A) receptor current: a role for GABA uptake transporters.
2006,
Pubmed
Otis,
Modulation of decay kinetics and frequency of GABAA receptor-mediated spontaneous inhibitory postsynaptic currents in hippocampal neurons.
1992,
Pubmed
Papandreou,
GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy.
2016,
Pubmed
Pavlov,
Tonic GABA(A) receptor-mediated signalling in temporal lobe epilepsy.
2013,
Pubmed
Persohn,
Comparative molecular neuroanatomy of cloned GABAA receptor subunits in the rat CNS.
1992,
Pubmed
Phulera,
Cryo-EM structure of the benzodiazepine-sensitive α1β1γ2S tri-heteromeric GABAA receptor in complex with GABA.
2018,
Pubmed
Pirker,
GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain.
2000,
Pubmed
Plested,
Single-channel study of the spasmodic mutation alpha1A52S in recombinant rat glycine receptors.
2007,
Pubmed
Shen,
De novo GABRG2 mutations associated with epileptic encephalopathies.
2017,
Pubmed
Sigel,
The Benzodiazepine Binding Sites of GABAA Receptors.
2018,
Pubmed
Steudle,
A novel de novo variant of GABRA1 causes increased sensitivity for GABA in vitro.
2020,
Pubmed
Wirrell,
Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel.
2017,
Pubmed
Wisden,
GABAA receptor channels: from subunits to functional entities.
1992,
Pubmed
Wu,
Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release.
2003,
Pubmed
Wu,
GABA transaminase inhibition induces spontaneous and enhances depolarization-evoked GABA efflux via reversal of the GABA transporter.
2001,
Pubmed